摘要
目的:探讨转录因子T-bet/GATA-3在哮喘发病中的作用机理,分析以T-bet/GATA-3为靶标的哮喘治疗手段。方法:总结近10年关于T-bet/GATA-3在哮喘发病中的机理研究及以此为靶标治疗哮喘的相关文章,进行分析、归纳。结果:T-bet/GATA-3作为哮喘发病中的转录因子,能够客观地反映Th1/Th2细胞分化和Th1型细胞因子、Th2型细胞因子的变化。以其为靶标治疗哮喘的方式近年取得的进展主要有生物制剂、免疫疗法、中医药、以及神经生长因子、寡核苷酸、转录因子圈套策略等分子和基因水平的治疗方法。结论:以转录因子T-bet/GATA-3为靶标的哮喘治疗手段近年取得较多进展,提示在转录水平将Th0细胞向Th1/Th2细胞分化这个环节作为治疗疾病的靶点,可能成为延长哮喘缓解期、减少复发的关键。
Objectives ： To probe into the mechanism of transcription factors T - bet/GATA - 3 in occurrence of bron- chial asthma, and analyze the relative treatment progress targeting at T - bet/GATA - 3. Methods ： Relative articles about mechanism of T - bet/GATA - 3 in occurrence of asthma and treatment progress on asthma targeting at T - bet/GATA - 3 published in the recent 10 years were reviewed, summarized and analyzed. Results： As transcription factors in occur- rence of asthma, T - bet and GATA - 3 may objectively reflect the differentiation of Thl/Th2 cells, and Thl and Th2 cy- tokines changes. Treatment progress targeting at T - bet/GATA - 3 is mainly about biological agent, immunotherapy and molecular and genetic level therapies including nerve growth factor, oligonucleotides, Chinese medicine and transcription factor ＂decoy＂ strategy. Conclusions ： Treatment progress aiming at T - bet/GATA - 3 in asthma indicates that taking T - bet/GATA - 3 as the target of Thl/Th2 cells differentiation may be the key point of expanding remission stage and reduce the recurrence rate of asthma.
出处
《中华中医药学刊》
CAS
2012年第6期1231-1233,共3页
Chinese Archives of Traditional Chinese Medicine
基金
国家自然科学基金资助项目(30873286)
